Your browser doesn't support javascript.
loading
Mast Cell Diseases in Practice and Research: Issues and Perspectives Raised by Patients and Their Recommendations to the Scientific Community and Beyond.
Jennings, Susan V; Finnerty, Celeste C; Hobart, Jessica S; Martín-Martínez, Mercedes; Sinclair, Kristin A; Slee, Valerie M; Agopian, Julie; Akin, Cem; Álvarez-Twose, Ivan; Bonadonna, Patrizia; Bowman, Angela S; Brockow, Knut; Bumbea, Horia; de Haro, Claudia; Fok, Jie Shen; Hartmann, Karin; Hegmann, Nicole; Hermine, Olivier; Kalisiak, Monika; Katelaris, Constance H; Kurz, Jacqueline; Marcis, Patrizia; Mayne, David; Mendoza, David; Moussy, Alain; Mudretzkyj, Genija; Vaia, Nicoleta Nidelea; Niedoszytko, Marek; Elberink, Hanneke Oude; Orfao, Alberto; Radia, Deepti H; Rosenmeier, Sophie; Ribada, Eugenia; Schinhofen, Waltraud; Schwaab, Juliana; Siebenhaar, Frank; Triggiani, Massimo; Tripodo, Giuseppe; Velazquez, Rocio; Wielink, Yvon; Wimazal, Friedrich; Yigit, Timo; Zubrinich, Celia; Valent, Peter.
Afiliación
  • Jennings SV; The Mast Cell Disease Society, Inc. (DBA The Mastocytosis Society, Inc.), Sterling, Mass. Electronic address: susan.jennings@tmsforacure.org.
  • Finnerty CC; The Mast Cell Disease Society, Inc. (DBA The Mastocytosis Society, Inc.), Sterling, Mass; Department of Surgery, University of Texas Medical Branch, Galveston, Texas.
  • Hobart JS; The UK Mastocytosis Support Group, London, United Kingdom.
  • Martín-Martínez M; Spanish Association of Mastocytosis and Related Diseases (AEDM), Madrid, Spain; Medicinal Chemistry Institute (IQM-CSIC), Madrid, Spain.
  • Sinclair KA; The Australasian Mastocytosis Society, Port Macquarie, New South Wales, Australia.
  • Slee VM; The Mast Cell Disease Society, Inc. (DBA The Mastocytosis Society, Inc.), Sterling, Mass.
  • Agopian J; French Association for Research Initiatives on Mast Cells and Mastocytosis (AFIRMM), Paris, France.
  • Akin C; Division of Allergy and Clinical Immunology, Department of Medicine, University of Michigan, Ann Arbor, Mich.
  • Álvarez-Twose I; Institute of Mastocytosis Studies of Castilla-La Mancha (CLMast) and CIBERONC, Virgen del Valle Hospital, Toledo, Spain; Spanish Network on Mastocytosis (REMA), Toledo and Salamanca, Spain.
  • Bonadonna P; Allergy Unit, Verona University Hospital, Verona, Italy.
  • Bowman AS; The Mast Cell Disease Society, Inc. (DBA The Mastocytosis Society, Inc.), Sterling, Mass; Department of Health and Human Performance, Middle Tennessee State University, Murfreesboro, Tenn.
  • Brockow K; Department of Dermatology and Allergy Biederstein, Faculty of Medicine, Technical University of Munich, Munich, Germany.
  • Bumbea H; European Center of Excellence in Mastocytosis, Hematological Rare Disease Center, Department of Hematology, Emergency University Hospital Bucharest, Bucharest, Romania.
  • de Haro C; Mexican Association of Mastocytosis, AC, Mexico City, Mexico.
  • Fok JS; Allergy and Clinical Immunology, Box Hill Hospital, Eastern Health, Box Hill, Victoria, Australia; Immunology and Allergy, Monash Medical Centre, Monash Health, Clayton, Victoria, Australia.
  • Hartmann K; Division of Allergy, Department of Dermatology, University Hospital Basel and University of Basel, Basel, Switzerland.
  • Hegmann N; Mastocytosis Self-Support Network, eV, Odenthal, Germany.
  • Hermine O; Imagine Institute Université de Paris Descartes, Sorbonne, Institut National de la Santé et de la Recherche Médicale, Centre National de Référence des Mastocytoses (CEREMAST), Hôpital Necker, Assistance Publique Hôpitaux de Paris, Paris, France.
  • Kalisiak M; Mastocytosis Society Poland, Warsaw, Poland.
  • Katelaris CH; Department of Medicine, Immunology and Allergy Unit, Campbelltown Hospital, Campbelltown, New South Wales, Australia; Immunology and Allergy Unit, School of Medicine, Western Sydney University, Campbelltown, New South Wales, Australia.
  • Kurz J; Mastocytosis Self-Support Network, eV, Odenthal, Germany.
  • Marcis P; Italian Mastocytosis Association, Turin, Italy.
  • Mayne D; The Australasian Mastocytosis Society, Port Macquarie, New South Wales, Australia.
  • Mendoza D; Pediatric Allergy and Clinical Immunology, Instituto Nacional de Pediátria, Mexico City, Mexico.
  • Moussy A; French Association for Research Initiatives on Mast Cells and Mastocytosis (AFIRMM), Paris, France.
  • Mudretzkyj G; Austrian Mastocytosis Support Group, Vienna, Austria.
  • Vaia NN; Mastocytosis Support Association Romania, Bucharest, Romania.
  • Niedoszytko M; Allergology Department, Medical University of Gdansk, Gdansk, Poland.
  • Elberink HO; Department of Allergology, Groningen Research Institute for Asthma and COPD (GRIAC), University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
  • Orfao A; Spanish Network on Mastocytosis (REMA), Toledo and Salamanca, Spain; Servicio Central de Citometria, Centro de Investigacion del Cancer (IBMCC; CSIC/USAL), Instituto Biosanitario de Salamanca (IBSAL), CIBERONC and Department of Medicine, University of Salamanca, Salamanca, Spain.
  • Radia DH; Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom.
  • Rosenmeier S; Austrian Mastocytosis Support Group, Vienna, Austria.
  • Ribada E; Spanish Association of Mastocytosis and Related Diseases (AEDM), Madrid, Spain.
  • Schinhofen W; Self-Support Association Mastocytosis eV, Toenisvorst, Germany.
  • Schwaab J; Department of Hematology and Oncology, University Hospital Mannheim, Mannheim, Germany.
  • Siebenhaar F; Institute of Allergology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany; Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Allergology and Immunology, Berlin, Germ
  • Triggiani M; Division of Allergy and Clinical Immunology, University of Salerno, Salerno, Italy.
  • Tripodo G; Italian Mastocytosis Association, Turin, Italy.
  • Velazquez R; Mexican Association of Mastocytosis, AC, Mexico City, Mexico.
  • Wielink Y; Mastocytosis Association Netherlands, Almere, The Netherlands.
  • Wimazal F; Department of Obstetrics and Gynecology, Medical University of Vienna, Vienna, Austria.
  • Yigit T; Self-Support Association Mastocytosis eV, Toenisvorst, Germany.
  • Zubrinich C; Allergy and Clinical Immunology, Alfred Health, Melbourne, Victoria, Australia.
  • Valent P; Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria; Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria.
J Allergy Clin Immunol Pract ; 10(8): 2039-2051, 2022 08.
Article en En | MEDLINE | ID: mdl-35777651
ABSTRACT

BACKGROUND:

Since 2010, patients and physicians have collaborated to understand unmet needs of patients with mast cell diseases, incorporating mastocytosis and mast cell activation disorders, which include mast cell activation syndromes.

OBJECTIVE:

This Open Innovation in Science project aims to expand understanding of the needs of patients affected by mast cell diseases, and encourage global communication among patient advocacy groups, physicians, researchers, industry, and government. A major aim is to support the scientific community's efforts to improve diagnosis, management, therapy, and patients' quality of life by addressing unmet needs.

METHODS:

In collaboration with mast cell disease specialists, 13 patient advocacy groups from 12 countries and regions developed lists of top patient needs. A core team of leaders from patient advocacy groups collected and analyzed the data and proposed possible actions to address patient needs.

RESULTS:

Findings identified similarities and differences among participating countries in unmet needs between patients with mastocytosis and those with mast cell activation syndromes. Issues emphasized struggles relating to the nature and rarity of mast cell diseases, their impact on quality of life, the diagnostic process, access to appropriate care, more effective treatment, and the need for research.

CONCLUSIONS:

Solutions vary across countries because situations differ, in particular regarding the existence of and access to centers of excellence and reference centers. Multifaceted mast cell activation syndrome barriers necessitate innovative approaches to improve access to appropriate care. The outcomes of this project should greatly support scientists and clinicians in their efforts to improve diagnosis, management, and treatment of patients with mastocytosis and mast cell activation disorders.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Mastocitosis / Trastornos de la Activación de los Mastocitos Tipo de estudio: Diagnostic_studies / Guideline / Prognostic_studies Límite: Humans Idioma: En Revista: J Allergy Clin Immunol Pract Año: 2022 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Mastocitosis / Trastornos de la Activación de los Mastocitos Tipo de estudio: Diagnostic_studies / Guideline / Prognostic_studies Límite: Humans Idioma: En Revista: J Allergy Clin Immunol Pract Año: 2022 Tipo del documento: Article